التفاصيل البيبلوغرافية
| العنوان: |
Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis. |
| المؤلفون: |
Craemer, Ann-Sophie De, Renson, Thomas, Deroo, Liselotte, Praet, Liesbet Van, Cypers, Heleen, Varkas, Gaëlle, Joos, Rik, Devinck, Mieke, Gyselbrecht, Lieve, Peene, Isabelle, Thevissen, Kristof, Costantino, Félicie, D'Agostino, Maria-Antonietta, Lenaerts, Jan, Carron, Philippe, Bosch, Filip Van den, Elewaut, Dirk |
| المصدر: |
Rheumatology; Aug2022, Vol. 61 Issue 8, p3279-3288, 10p |
| مصطلحات موضوعية: |
MUSCULOSKELETAL system diseases, SCIENTIFIC observation, CONFIDENCE intervals, TIME, ANKYLOSIS, SPONDYLOARTHROPATHIES, NEUROLOGIC manifestations of general diseases, DESCRIPTIVE statistics, CLUSTER analysis (Statistics), ODDS ratio, PHENOTYPES, LONGITUDINAL method, LATENT structure analysis |
| مستخلص: |
Objectives To delineate the impact of peripheral musculoskeletal manifestations on stratification of disease phenotype and outcome in new-onset spondyloarthritis (SpA), using a prospective observational nationwide inception cohort, the BelGian Inflammatory Arthritis and spoNdylitis cohorT (Be-Giant). Methods Newly diagnosed adult SpA patients, fulfilling the Assessment of SpondyloArthritis International Society (ASAS) criteria for axial or peripheral SpA, were included in Be-Giant and prospectively followed every six months. Peripheral involvement (defined as arthritis, enthesitis and/or dactylitis) was determined in relation to clinically similar patient subsets at baseline and disease activity patterns during two-year follow-up, identified through K-means cluster analysis and latent class growth analysis. Results From November 2010 to March 2020, 367 patients were enrolled in Be-Giant, of whom 162 (44%) had peripheral manifestations. Two patient clusters [A, axial predominant (n = 248) and B, peripheral predominant (n = 119)] were identified at diagnosis. Longitudinal analysis (n = 115) revealed two trajectories of disease activity in each cluster: one with persistently high disease activity over time ('High'), the other rapidly evolving to low disease activity ('Low'). In cluster A patients, peripheral manifestations predisposed to the 'High' trajectory [odds ratio (OR) = 2.0, 95% CI: 1.3, 3.1, P = 0.001], despite more rapid initiation of biologics compared with patients without peripheral manifestations (hazard ratio (HR) = 2.1, 95% CI: 1.0, 4.4, P = 0.04 – Cox proportional-hazards model). Conclusion Peripheral musculoskeletal manifestations are major determinants of phenotypical diversity in new-onset SpA. Intriguingly, stratification of axial SpA according to concomitant peripheral involvement identified an endotype with an unfavorable outcome despite more prompt therapeutic intensification with biologics. These observations justify an endotype-tailored approach beyond current ASAS/EULAR management recommendations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Rheumatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder